Yixintang Pharmaceutical Group 将来の成長

Future 基準チェック /36

Yixintang Pharmaceutical Group利益と収益がそれぞれ年間45.8%と13.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に11.6% 45.7%なると予測されています。

主要情報

45.8%

収益成長率

45.7%

EPS成長率

Consumer Retailing 収益成長	42.2%
収益成長率	13.2%
将来の株主資本利益率	11.6%
アナリストカバレッジ	Good
最終更新日	19 Nov 2024

今後の成長に関する最新情報

Recent updates

Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear

Nov 06

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

Sep 25

These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Jul 15

Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Jun 29

Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Jun 13

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Jun 13

Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

May 27

Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

May 03

Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Apr 15

Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Mar 06

業績と収益の成長予測

SZSE:002727 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	24,688	937	1,180	1,839	11
12/31/2025	21,374	790	1,119	2,003	12
12/31/2024	18,396	449	898	1,123	8
9/30/2024	18,157	156	1,762	2,015	N/A
6/30/2024	18,010	327	2,086	2,355	N/A
3/31/2024	18,044	552	1,985	2,269	N/A
12/31/2023	17,380	549	1,862	2,115	N/A
9/30/2023	18,219	1,019	1,971	2,361	N/A
6/30/2023	18,142	1,096	2,234	2,553	N/A
3/31/2023	17,872	1,070	2,402	2,733	N/A
1/1/2023	17,432	1,010	2,148	2,497	N/A
9/30/2022	16,115	835	2,125	2,509	N/A
6/30/2022	15,851	816	1,537	1,947	N/A
3/31/2022	15,154	840	1,295	1,668	N/A
1/1/2022	14,587	922	1,400	1,792	N/A
9/30/2021	13,916	950	815	1,120	N/A
6/30/2021	13,329	897	610	928	N/A
3/31/2021	12,998	846	690	988	N/A
12/31/2020	12,656	790	753	1,033	N/A
9/30/2020	12,056	724	827	1,023	N/A
6/30/2020	11,448	683	1,077	1,257	N/A
3/31/2020	10,978	633	984	1,185	N/A
12/31/2019	10,479	604	776	983	N/A
9/30/2019	10,219	587	838	1,017	N/A
6/30/2019	9,945	566	719	892	N/A
3/31/2019	9,585	565	828	988	N/A
1/1/2019	9,176	521	480	636	N/A
9/30/2018	8,768	525	481	619	N/A
6/30/2018	8,391	499	N/A	579	N/A
3/31/2018	8,116	457	N/A	330	N/A
12/31/2017	7,751	423	N/A	391	N/A
9/30/2017	7,316	386	N/A	166	N/A
6/30/2017	6,949	373	N/A	44	N/A
3/31/2017	6,584	345	N/A	134	N/A
12/31/2016	6,249	353	N/A	193	N/A
9/30/2016	5,971	379	N/A	124	N/A
6/30/2016	5,774	369	N/A	220	N/A
3/31/2016	5,600	361	N/A	163	N/A
12/31/2015	5,321	346	N/A	187	N/A
9/30/2015	5,080	323	N/A	234	N/A
6/30/2015	4,854	314	N/A	58	N/A
3/31/2015	4,589	310	N/A	34	N/A
12/31/2014	4,428	297	N/A	176	N/A
9/30/2014	4,236	292	N/A	211	N/A
6/30/2014	3,995	279	N/A	228	N/A
3/31/2014	3,792	253	N/A	284	N/A
12/31/2013	3,547	241	N/A	228	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 002727の予測収益成長率 (年間45.8% ) は貯蓄率 ( 2.8% ) を上回っています。

収益対市場: 002727の収益 ( 45.8% ) はCN市場 ( 26.2% ) よりも速いペースで成長すると予測されています。

高成長収益: 002727の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 002727の収益 ( 13.2% ) CN市場 ( 13.8% ) よりも低い成長が予測されています。

高い収益成長: 002727の収益 ( 13.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 002727の自己資本利益率は、3年後には低くなると予測されています ( 11.6 %)。

Yixintang Pharmaceutical Group 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Price target decreased by 9.0% to CN¥15.14

Consensus EPS estimates fall by 26%

Consensus EPS estimates fall by 32%

Price target decreased by 10% to CN¥20.81

Consensus revenue estimates decrease by 11%

Price target decreased by 8.1% to CN¥35.37

Recent updates

Yixintang Pharmaceutical Group's (SZSE:002727) Soft Earnings Are Actually Better Than They Appear

Price target decreased by 9.0% to CN¥15.14

Consensus EPS estimates fall by 26%

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS misses analyst expectations

Yixintang Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 18%

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings

Consensus EPS estimates fall by 32%

Price target decreased by 10% to CN¥20.81

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) commences an Equity Buyback Plan for CNY 150 million worth of its shares, under the authorization approved on July 2, 2024.

Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727) commences an Equity Buyback Plan for CNY 150 million worth of its shares, under the authorization approved on July 2, 2024.

These 4 Measures Indicate That Yixintang Pharmaceutical Group (SZSE:002727) Is Using Debt Reasonably Well

Now 20% overvalued

Yixintang Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Some Investors May Be Worried About Yixintang Pharmaceutical Group's (SZSE:002727) Returns On Capital

Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Intrinsic Value Is Potentially 26% Below Its Share Price

Market Cool On Yixintang Pharmaceutical Group Co., Ltd.'s (SZSE:002727) Earnings Pushing Shares 27% Lower

Yixintang Pharmaceutical Group (SZSE:002727) Is Due To Pay A Dividend Of CN¥0.40

Dividend of CN¥0.40 announced

Yixintang Pharmaceutical Group Co., Ltd. Announces Dividend Implementation for 2023, Payable on 30 May 2024

Yixintang Pharmaceutical Group's (SZSE:002727) Conservative Accounting Might Explain Soft Earnings

Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2024

Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, May 21, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investors Holding Back On Yixintang Pharmaceutical Group Co., Ltd. (SZSE:002727)

Yixintang Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥0.92 (vs CN¥1.70 in FY 2022)

Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Now 21% undervalued after recent price drop

Yixintang Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Consensus revenue estimates decrease by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.40 in 2Q 2022)

Price target decreased by 8.1% to CN¥35.37

Yixintang Pharmaceutical Group Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 26 May 2023

Yixintang Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2022

Full year 2022 earnings released: EPS: CN¥1.70 (vs CN¥1.56 in FY 2021)

Price target increased to CN¥38.51

Investor sentiment improved over the past week

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Price target decreased to CN¥33.64

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to CN¥40.40

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥46.85

High number of new directors

Yixintang Pharmaceutical Group Co., Ltd. Proposes Cash Dividend on A Shares for the Year 2021, Payable on April 29, 2022

Yixintang Pharmaceutical Group Co., Ltd. Approves Profit Distribution

Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 20, 2022

Price target decreased to CN¥46.85

Yixintang Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.33 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.37 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.44 (vs CN¥0.36 in 1Q 2020)

Price target increased to CN¥50.86

Investor sentiment improved over the past week

Yixintang Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.06 in FY 2019)

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.06 in FY 2019)